title: Calcium and Magnesium Use for Oxaliplatin-Induced Neuropathy: A Case Study to Assess How Quickly Evidence Translates Into Practice.
abstract: Substantial research efforts have focused on methods of treating and preventing oxaliplatin-associated neuropathy, the dose-limiting toxicity associated with this drug. Administration of intravenous calcium and magnesium (CaMg) before and after oxaliplatin has been the most studied approach to preventing oxaliplatin-induced neuropathy. Although early reports demonstrated potential benefit, subsequent larger trials failed to confirm the efficacy of CaMg in preventing this adverse effect. This article explores how accumulating evidence for and against the use of CaMg for preventing oxaliplatin-induced neuropathy has impacted clinical practice.
authors.affiliation: From the Department of Oncology, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, and Health Care Policy & Research, Mayo Clinic, Rochester, Minnesota; and Optum Labs, Cambridge, Massachusetts.
authors.forename: Deirdre R
authors.initials: DR
authors.lastname: Pachman
authors.affiliation: From the Department of Oncology, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, and Health Care Policy & Research, Mayo Clinic, Rochester, Minnesota; and Optum Labs, Cambridge, Massachusetts.
authors.forename: Kathryn
authors.initials: K
authors.lastname: Ruddy
authors.affiliation: From the Department of Oncology, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, and Health Care Policy & Research, Mayo Clinic, Rochester, Minnesota; and Optum Labs, Cambridge, Massachusetts.
authors.forename: Lindsey R
authors.initials: LR
authors.lastname: Sangaralingham
authors.affiliation: From the Department of Oncology, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, and Health Care Policy & Research, Mayo Clinic, Rochester, Minnesota; and Optum Labs, Cambridge, Massachusetts.
authors.forename: Axel
authors.initials: A
authors.lastname: Grothey
authors.affiliation: From the Department of Oncology, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, and Health Care Policy & Research, Mayo Clinic, Rochester, Minnesota; and Optum Labs, Cambridge, Massachusetts. From the Department of Oncology, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, and Health Care Policy & Research, Mayo Clinic, Rochester, Minnesota; and Optum Labs, Cambridge, Massachusetts.
authors.forename: Nilay D
authors.initials: ND
authors.lastname: Shah
authors.affiliation: From the Department of Oncology, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, and Health Care Policy & Research, Mayo Clinic, Rochester, Minnesota; and Optum Labs, Cambridge, Massachusetts.
authors.forename: Andreas S
authors.initials: AS
authors.lastname: Beutler
authors.affiliation: From the Department of Oncology, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, and Health Care Policy & Research, Mayo Clinic, Rochester, Minnesota; and Optum Labs, Cambridge, Massachusetts.
authors.forename: Joleen M
authors.initials: JM
authors.lastname: Hubbard
authors.affiliation: From the Department of Oncology, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, and Health Care Policy & Research, Mayo Clinic, Rochester, Minnesota; and Optum Labs, Cambridge, Massachusetts.
authors.forename: Charles L
authors.initials: CL
authors.lastname: Loprinzi
mesh_terms: D000067575:Administrative Claims, Healthcare; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D035843:Biomedical Research; D002118:Calcium / Q000627:therapeutic use*; D000068818:Cetuximab / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D006801:Humans; D008274:Magnesium / Q000627:therapeutic use*; D008910:Minnesota; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D000077150:Oxaliplatin; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced / Q000517:prevention & control*; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data / Q000639:trends; D012189:Retrospective Studies; D057170:Translational Research, Biomedical
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D008274:Magnesium; D000068818:Cetuximab; D002945:Cisplatin; D002118:Calcium